Difference between revisions of "Paclitaxel (Taxol)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
|||
| Line 7: | Line 7: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Basal cell and squamous cell skin cancer]] | ||
| + | *[[Bladder cancer]] | ||
| + | *[[Breast cancer]] | ||
| + | *[[Cervical cancer]] | ||
| + | *[[Esophageal cancer]] | ||
| + | *[[Head and neck cancer]] | ||
| + | *[[Melanoma]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Ovarian cancer]] | ||
| + | *[[Penile cancer]] | ||
| + | *[[Prostate cancer]] | ||
| + | *[[Sarcoma]] | ||
| + | *[[Small cell lung cancer]] | ||
| + | *[[Testicular cancer]] | ||
| + | *[[Thymoma]] | ||
| + | *[[Unknown primary]] | ||
| + | *[[Uterine cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 19:58, 21 June 2013
Also known as Onxal.
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Basal cell and squamous cell skin cancer
- Bladder cancer
- Breast cancer
- Cervical cancer
- Esophageal cancer
- Head and neck cancer
- Melanoma
- Non-small cell lung cancer
- Ovarian cancer
- Penile cancer
- Prostate cancer
- Sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Unknown primary
- Uterine cancer
Patient drug information
- Paclitaxel (Taxol) package insert PDF pages 50-53[1]
- Paclitaxel (Taxol) patient drug information (Chemocare)[3]
- Paclitaxel (Taxol) patient drug information (UpToDate)[4]